Wedge Capital Management L L P NC Grows Position in Envista Holdings Co. (NYSE:NVST)

Wedge Capital Management L L P NC raised its position in Envista Holdings Co. (NYSE:NVST) by 0.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 102,309 shares of the company’s stock after buying an additional 569 shares during the quarter. Wedge Capital Management L L P NC owned approximately 0.06% of Envista worth $2,462,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Foundry Partners LLC purchased a new position in shares of Envista in the 4th quarter valued at approximately $3,571,000. Raymond James & Associates lifted its stake in shares of Envista by 820.6% in the 4th quarter. Raymond James & Associates now owns 408,218 shares of the company’s stock worth $9,822,000 after acquiring an additional 363,875 shares during the period. River Road Asset Management LLC acquired a new position in shares of Envista during the fourth quarter worth about $54,931,000. DAVENPORT & Co LLC purchased a new position in Envista during the fourth quarter worth about $13,233,000. Finally, Blueshift Asset Management LLC boosted its holdings in Envista by 168.7% in the 3rd quarter. Blueshift Asset Management LLC now owns 41,524 shares of the company’s stock valued at $1,158,000 after purchasing an additional 26,073 shares in the last quarter.

Wall Street Analyst Weigh In

Several research firms have recently commented on NVST. SVB Leerink initiated coverage on Envista in a report on Monday, February 26th. They issued an “underperform” rating and a $19.00 price target for the company. TheStreet downgraded shares of Envista from a “c” rating to a “d+” rating in a report on Wednesday, February 7th. UBS Group assumed coverage on shares of Envista in a report on Friday, January 5th. They set a “neutral” rating and a $26.00 price objective on the stock. Leerink Partnrs reiterated an “underperform” rating on shares of Envista in a research report on Monday, February 26th. Finally, William Blair downgraded Envista from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 8th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $29.60.

Envista Trading Up 0.3 %

Envista stock opened at $20.28 on Thursday. The company has a quick ratio of 1.90, a current ratio of 2.23 and a debt-to-equity ratio of 0.33. The firm has a 50-day moving average price of $21.05 and a two-hundred day moving average price of $22.77. The firm has a market capitalization of $3.49 billion, a price-to-earnings ratio of -33.25, a PEG ratio of 3.77 and a beta of 1.35. Envista Holdings Co. has a 52-week low of $18.95 and a 52-week high of $39.09.

Envista (NYSE:NVST) last issued its quarterly earnings results on Wednesday, February 7th. The company reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.04). The company had revenue of $645.60 million during the quarter, compared to analyst estimates of $638.37 million. Envista had a positive return on equity of 6.31% and a negative net margin of 3.90%. The company’s revenue was down 2.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.52 earnings per share. Sell-side analysts expect that Envista Holdings Co. will post 1.43 earnings per share for the current year.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.